Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement.

Solomon DH, Shadick NA, Weinblatt ME, Zak A, Frits M, Franklin JM.

Arthritis Res Ther. 2017 Jun 13;19(1):130. doi: 10.1186/s13075-017-1330-0.

2.

Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries.

Solomon DH, Shadick NA, Weinblatt ME, Frits M, Iannaccone C, Zak A, Korzenik JR.

BMC Med Res Methodol. 2017 Apr 17;17(1):59. doi: 10.1186/s12874-017-0343-3.

3.

Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.

Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, Donlin LT, Henderson LA, Wei K, Mizoguchi F, Teslovich NC, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Lee YC, Todd DJ, Bykerk VP, Goodman SM, Pernis AB, Ivashkiv LB, Karlson EW, Nigrovic PA, Filer A, Buckley CD, Lederer JA, Raychaudhuri S, Brenner MB.

Nature. 2017 Feb 1;542(7639):110-114. doi: 10.1038/nature20810.

4.

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S.

Arthritis Rheumatol. 2016 Dec;68(12):2857-2866. doi: 10.1002/art.39808.

5.

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.

Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10.

6.

Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration.

Schiff M, Weinblatt ME, Valente R, Citera G, Maldonado M, Massarotti E, Yazici Y, Fleischmann R.

RMD Open. 2016 Apr 19;2(1):e000210. doi: 10.1136/rmdopen-2015-000210. eCollection 2016.

7.

Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.

Pope J, Bingham CO 3rd, Fleischmann RM, Dougados M, Massarotti EM, Wollenhaupt J, Duncan B, Coteur G, Weinblatt ME.

Arthritis Res Ther. 2015 Nov 27;17:343. doi: 10.1186/s13075-015-0849-1.

8.

Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia.

Lee YC, Hackett J, Frits M, Iannaccone CK, Shadick NA, Weinblatt ME, Segurado OG, Sasso EH.

Rheumatology (Oxford). 2016 Apr;55(4):640-8. doi: 10.1093/rheumatology/kev388. Epub 2015 Nov 25.

9.

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.

Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijtens K, Dougados M.

Arthritis Res Ther. 2015 Nov 15;17:325. doi: 10.1186/s13075-015-0841-9.

10.

Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.

Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, Furst DE.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):907-13. doi: 10.1002/acr.22763.

11.

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.

Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH.

Ann Rheum Dis. 2016 Apr;75(4):709-14. doi: 10.1136/annrheumdis-2015-207942. Epub 2015 Sep 10.

12.

Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.

Alemao E, Joo S, Kawabata H, Al MJ, Allison PD, Rutten-van Mölken MP, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME.

Arthritis Care Res (Hoboken). 2016 Mar;68(3):308-17. doi: 10.1002/acr.22678.

13.

An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score.

Desai RJ, Solomon DH, Weinblatt ME, Shadick N, Kim SC.

Arthritis Res Ther. 2015 Apr 13;17:83. doi: 10.1186/s13075-015-0599-0.

14.

Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.

Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, Golzarri MF, Traslosheros A, Chu SG, Frits ML, Iannaccone CK, Koontz D, Fuhrman C, Weinblatt ME, El-Chemaly SY, Washko GR, Hunninghake GM, Choi AM, Dellaripa PF, Oddis CV, Shadick NA, Ascherman DP, Rosas IO.

Am J Respir Crit Care Med. 2015 Jun 15;191(12):1403-12. doi: 10.1164/rccm.201411-1950OC.

15.

The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.

Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, Shadick NS, Mehta NN.

J Am Heart Assoc. 2015 Jan 30;4(2). pii: e001588. doi: 10.1161/JAHA.114.001588.

16.
17.

Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.

Oswald M, Curran ME, Lamberth SL, Townsend RM, Hamilton JD, Chernoff DN, Carulli J, Townsend MJ, Weinblatt ME, Kern M, Pond CM, Lee A, Gregersen PK.

Arthritis Rheumatol. 2015 Feb;67(2):344-51. doi: 10.1002/art.38947.

18.

Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis.

Mjaavatten MD, Radner H, Yoshida K, Shadick NA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, Solomon DH.

J Rheumatol. 2014 Dec;41(12):2370-8. doi: 10.3899/jrheum.140306. Epub 2014 Oct 15.

19.

Clinical characteristics of RA patients with secondary SS and association with joint damage.

Brown LE, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Liao KP.

Rheumatology (Oxford). 2015 May;54(5):816-20. doi: 10.1093/rheumatology/keu400. Epub 2014 Oct 13.

20.

Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs.

Mjaavatten MD, Radner H, Yoshida K, Shadick NA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, Solomon DH.

Semin Arthritis Rheum. 2015 Feb;44(4):399-404. doi: 10.1016/j.semarthrit.2014.08.003. Epub 2014 Aug 27.

Supplemental Content

Loading ...
Support Center